Drug profile · INN
glimepiride
ARX-GLIMEPIRIDE
glimepiride (ARX-GLIMEPIRIDE) is a sulfonylurea receptor 1, kir6.2 blocker. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — glimepiride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 2
- Programs
- 7
- Data quality
- 0.89
Quick answer
glimepiride (ARX-GLIMEPIRIDE) is a sulfonylurea receptor 1, kir6.2 blocker. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Sulfonylurea receptor 1, Kir6.2 blocker
Primary target: Sulfonylurea receptor 1, Kir6.2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is glimepiride?
glimepiride (ARX-GLIMEPIRIDE) is a sulfonylurea receptor 1, kir6.2 blocker. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for glimepiride?
ARX-GLIMEPIRIDE is a marketed brand name for glimepiride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of glimepiride?
glimepiride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.